Epidyolex® (cannabidiol) GB Prescribing Information
Adverse events should be reported. Healthcare Professionals are asked to report any suspected adverse events via their national reporting system.
For the UK, reporting forms and information can be found at
or search for Yellow Card MHRA in the Google Play or Apple App Store.
Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com
touchFEATURE Optimising clinical use of Epidyolex® (cannabidiol) for the adjunctive treatment of specific DEEs
Watch leading epilepsy experts Prof. Heirdrun Potschka and Prof. Stefano Meletti discuss optimising clinical use of Epidyolex® (cannabidiol) for the adjunctive treatment of specific DEEs, explain its mechanism of action, pharmacokinetic characteristics, and review the implications for clinical use.
By clicking on the link yellowcard.mhra.gov.uk you will be leaving the touchneurology.com website which is neither owned nor controlled by Jazz Pharmaceuticals. Jazz Pharmaceuticals is not responsible for the content of this third party website
Understanding the pharmacology of Epidyolex® (cannabidiol)
Watch Prof. Heidrun Potschka explain the mechanism of action of Epidyolex® (cannabidiol) in the treatment of seizures; describe its pharmacokinetic characteristics and metabolism; and discuss the clinical relevance of potential drug-drug interactions and their implications for clinical use
view bio and disclosures 1/2 Next ChapterOptimise the clinical use of Epidyolex® (cannabidiol)
Watch Prof. Stefano Meletti present a case of Lennox-Gastaut syndrome, highlighting the optimal use of Epidyolex® (cannabidiol) to reduce medication burden, improve seizure control, and increase patient quality of life.
view bio and disclosures 2/2 Leave FeedbackAdverse Events
Adverse Events
By clicking on the link yellowcard.mhra.gov.uk you will be leaving the touchneurology.com website which is neither owned nor controlled by Jazz Pharmaceuticals. Jazz Pharmaceuticals is not responsible for the content of this third party website
Overview & Learning Objectives
Overview
Epidyolex® (cannabidiol), is approved for use as adjunctive therapy of seizures associated with tuberous sclerosis complex for patients 2 years of age and older, and in conjunction with clobazam for seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.1 In this series of presentations, watch leading epilepsy experts Prof. Heidrun Potschka and Prof. Stefano Meletti discuss the optimal use of Epidyolex® (cannabidiol), explain its mechanism of action, pharmacokinetic charateristics, and review the implications for clinical use.
References
- Jazz Pharmaceuticals. Epidyolex® (cannabidiol) 100 mg/mL oral solution: prescribing information for Great Britain. Available at https://www.epidyolex.com/gb/prescribinginformation (opens on a third party website) (accessed 16 February 2024).
Learning Objectives
After watching this activity, participants should be better able to:
- Describe the indication, dosing and optimal use of Epidyolex® (cannabidiol) for the adjunctive treatment of specific DEEs
- Understand the mechanisms by which Epidyolex® (cannabidiol) can improve seizure control in people with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex
- Discuss the pharmacokinetic properties of Epidyolex® (cannabidiol), including its metabolism and drug-drug interactions, and explain their implications for clinical use
Faculty & Disclosures
Prof. Heidrun Potschka
Institute of Pharmacology, Toxicology and Pharmacy, Ludwig-Maximilians-University Munich, Munich Center for Neurosciences, Munich, Germany
Heidrun Potschka is Chair of Pharmacology, Toxicology and Pharmacy at the Ludwig-Maximilians University, Munich. Her research interests centre around the pathophysiology and pharmacology of epilepsy, with a special focus on the mechanisms of drug resistance. She is a member of the Research and Innovative Task Force at the International League Against Epilepsy, and has been an author on over 200 peer-reviewed publications.
Speaker and consulting fees: Angelini Pharma, Bayer, Eisai, Elanco, Galapagos, Jazz Pharmaceuticals, Lario/Epidarex Exeed, MSD and Zogenix. Funding for research collaborations: Bayer, Bial and Roche
Prof. Stefano Meletti
University of Modena, Italy
Stefano Meletti is Professor of Neurology and Head of the Neurology Department at the University of Modena, Italy. His research interests centre around epilepsy, sleep disorders and neuroimaging, for which he helped develop a specialist centre for advanced neuroimaging studies in patients with epilepsy. He has been the lead Investigator in several pharmacological and non-pharmacological clinical trials, and published over 200 manuscripts in peer-reviewed journals.
Participation in advisory boards, pharmaceutical industry-sponsored satellite symposia, events, etc. for: Angelini, Eisai, Jazz Pharmaceuticals and UCB Pharma